CJC-1295 (without DAC)

You can buy CJC-1295 no DAC from Peptide Lab as a lab-verified research peptide with 99.0% purity, for research purposes only. CJC-1295 no DAC (also known as Modified GRF 1-29) is a modified analogue of growth hormone-releasing hormone (GHRH). It is a widely studied research peptide in the field of growth hormone research and is supplied as a lyophilised powder, 10 mg per vial.

Who is CJC-1295 no DAC intended for?

CJC-1295 no DAC is intended for researchers and laboratories studying the GHRH signalling pathway and the regulation of growth hormone. It is often mentioned in conjunction with Ipamorelin; a ready-to-use CJC-1295 no DAC + Ipamorelin blend is also available. For the long-acting variant, see CJC-1295 with DAC.

Why Peptide Lab?

• Verified purity of 99.0% by HPLC and mass spectrometry.
• Batch documentation available; molecular weight per CoA.
• Lyophilised powder, 10 mg per vial.
• Fast, discreet EU delivery.

CJC-1295 no DAC is not a medicinal product and is not intended for human or animal consumption.

Specifications at a glance

• Form: freeze-dried powder
• Packaging: 10 mg per vial
• Purity: 99.0%
• Molecular weight: See CoA
• Laboratory certificate: available on request
• For laboratory and research purposes only

CJC-1295 no DAC is an analogue of the first 29 amino acids of GHRH (growth hormone-releasing hormone), with a few modifications that make the molecule more stable than natural GHRH. The addition of ‘no DAC’ indicates that the long-acting Drug Affinity Complex modification is absent, resulting in a shorter duration of action.

Mechanism of action under investigation

GHRH is the signal that triggers the pituitary gland to release growth hormone. In research, CJC-1295 no DAC is used to study this GHRH pathway and the pulsatile regulation of growth hormone. Its shorter duration of action makes it suitable for experiments in which a more natural, pulsatile signalling pattern is desired.

These mechanisms are based on preclinical research and describe the research context; they do not represent proven effects in humans.

The difference between the ‘no DAC’ and the DAC variants lies entirely in the duration of action: without the Drug Affinity Complex modification, the molecule is broken down more quickly, resulting in a shorter, more pulsatile signal. Researchers choose the variant that matches the signal pattern they wish to study.

CJC-1295 and the non-DAC variant (Modified GRF 1-29) have been extensively studied in research into the GHRH signalling pathway. They are often compared with and combined with growth hormone secretagogues such as Ipamorelin.

• Research focus: The GHRH receptor and the release of growth hormone.
• Research focus: pulsed, natural regulatory patterns.
• Research focus: combinations with secretagogues (preclinical).

Status and context

CJC-1295 without DAC is not authorised as a medicinal product and is supplied solely as research material. In the context of sport, GHRH analogues are on the World Anti-Doping Agency’s (WADA) Prohibited List. When conducting research, always document the purity and batch number to ensure that experiments remain reproducible and traceable.

The combination of a GHRH analogue with a secretagogue is a common area of research, as both act at different points along the same pathway. A pure starting material, documented for each batch, is essential for traceable results.

For researchers, the choice between the two options is therefore primarily a design decision that depends on the research question and the desired signal pattern.

CJC-1295 without DAC is supplied as a lyophilised powder and reconstituted in the laboratory using bacteriostatic water. The steps below describe only the laboratory procedures for research purposes.

1. 1Allow the vial and the bacteriostatic water to reach room temperature.
2. 2Wipe the rubber stoppers of both vials with an alcohol wipe.
3. 3Allow the bacteriostatic water to run slowly down the side of the vial; do not direct it straight onto the powder.
4. 4Gently swirl the vial until everything has dissolved; do not shake.
5. 5Store the solution in the fridge and label it with the date and batch number.

Items such as bacteriostatic water, insulin syringes and alcohol wipes can be found under ‘Lab & Accessories’. This is a laboratory instruction and does not constitute dosage advice for consumption.

Combining approaches in research

In research studies, CJC-1295 (no DAC) is often investigated alongside Ipamorelin, as the two act on growth hormone release via different mechanisms. For a ready-to-use combination, there is the CJC-1295 no DAC + Ipamorelin blend. Document each peptide separately.

Choose the right option

Decide in advance whether a short, pulsed signal (no DAC) or a long-duration signal (with DAC) is appropriate for your research question; this will determine which variant and which experimental design make sense.

Store CJC-1295 (without DAC) in powder form in a cool, dark place to ensure maximum stability.

Practical storage tips

• Powder form: freezer (-20 °C) for long-term storage; fridge (2–8 °C) for short-term storage.
• After reconstitution: store refrigerated (2–8 °C) and use within a few weeks.
• Avoid direct light, heat and repeated temperature changes.
• Write the reconstitution date and batch number on the vial.

Careful storage preserves the purity of the research material.